News & Updates

High-dose somatostatin analogues (SSAs) can be effective and well-tolerated second-line therapies in neuroendocrine tumours (NETs) progressing on standard-dose SSAs in selected cases, according to Dr Ingrid Mak of the University of Hong Kong, at the 7th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2024). 

New drug applications approved by US FDA as of 1-15 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The risk of new or recurrent cancer related to inflammatory bowel disease (IBD) treatment does not appear to be elevated for IBD patients with a history of breast cancer, according to a large retrospective study.

The fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy equecabtagene autoleucel (eque-cel) appears to induce early, deep, and lasting responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to the results of the phase Ib/II FUMANBA-1 trial.

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.